Nebula Research & Development LLC Takes $1.62 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Nebula Research & Development LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,584 shares of the biotechnology company's stock, valued at approximately $1,617,000.

Several other hedge funds also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC bought a new position in United Therapeutics in the fourth quarter worth $67,000. MassMutual Private Wealth & Trust FSB lifted its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Natixis bought a new position in United Therapeutics in the fourth quarter worth $85,000. Finally, Anchor Investment Management LLC lifted its position in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Trading Up 1.9 %

Shares of UTHR stock traded up $5.66 during trading hours on Monday, hitting $297.04. 410,281 shares of the company were exchanged, compared to its average volume of 447,897. The business has a 50 day moving average of $307.00 and a two-hundred day moving average of $346.00. United Therapeutics Co. has a 52 week low of $233.31 and a 52 week high of $417.82. The company has a market capitalization of $13.34 billion, a PE ratio of 13.05, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the firm earned $4.36 earnings per share. On average, research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on UTHR. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Finally, Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research note on Monday, April 21st. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $390.17.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. This trade represents a 23.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 74,500 shares of company stock valued at $24,472,050. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.